Should management of pneumonia be an indicator of quality of care?

Clinics in Chest Medicine

Volumn 32, Issue 3, 2011, Pages 575-589

  Metersky, Mark L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Community acquired pneumonia; Guideline; Guideline adherence; Performance measurement; Pneumonia, bacterial; Public reporting; Quality improvement; Quality indicators, Health care

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFTAROLINE; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GEMIFLOXACIN; GENTAMICIN; IMIPENEM; INFLUENZA VACCINE; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC THERAPY; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC TEST; EVIDENCE BASED PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; INFLUENZA; INFORMATION DISSEMINATION; LENGTH OF STAY; MEDICAL ASSESSMENT; MORTALITY; OXYGENATION; PATIENT CARE; PERFORMANCE MEASUREMENT SYSTEM; PHYSICIAN ATTITUDE; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; GUIDELINE ADHERENCE; HUMANS; INFLUENZA, HUMAN; LENGTH OF STAY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT READMISSION; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE; VACCINATION;

EID: 80051888629     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.05.005     Document Type: Review

References (60)

1. McGlynn E.A., Asch S.M., Adams J., et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003, 348(26):2635-2645.
2. Rewarding provider performance: aligning incentives in Medicare 2007, Committee on Redesigning Health Insurance Performance Measures, Payment and Performance Improvement Programs, The National Academies Press, Washington, DC.
3. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122(2):130-141.
4. Hospital Compare U.S. Department of Health and Human Services, Available at:, Accessed January 24, 2011. http://www.hospitalcompare.hhs.gov/.
5. Yende S., Angus D.C., Ali I.S., et al. Influence of comorbid conditions on long-term mortality after pneumonia in older people. J Am Geriatr Soc 2007, 55(4):518-525.
6. Frei C.R., Restrepo M.I., Mortensen E.M., et al. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006, 119(10):865-871.
7. Mortensen E.M., Restrepo M., Anzueto A., et al. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004, 117(10):726-731.
8. Ramirez J.A. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med 2005, 26(6):543-552.
9. Meehan T.P., Fine M.J., Krumholz H.M., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278(23):2080-2084.
10. Campbell S.G., Marrie T.J., Anstey R., et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003, 123(4):1142-1150.
11. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
12. Lindenauer P.K., Bernheim S.M., Grady J.N., et al. The performance of US hospitals as reflected in risk-standardized 30-day mortality and readmission rates for Medicare beneficiaries with pneumonia. J Hosp Med 2010, 5(6):E12-E18.
13. Arnold F.W., LaJoie A.S., Brock G.N., et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009, 169(16):1515-1524.
14. McCabe C., Kirchner C., Zhang H., et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009, 169(16):1525-1531.
15. Menendez R., Torres A., Zalacain R., et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005, 172(6):757-762.
16. Frei C.R., Attridge R.T., Mortensen E.M., et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther 2010, 32(2):293-299.
17. Bodi M., Rodriguez A., Sole-Violan J., et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005, 41(12):1709-1716.
18. Aujesky D., Fine M.J. Does guideline adherence for empiric antibiotic therapy reduce mortality in community-acquired pneumonia?. Am J Respir Crit Care Med 2005, 172(6):655-656.
19. Dean N.C., Silver M.P., Bateman K.A., et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001, 110(6):451-457.
20. Dean N.C., Bateman K.A., Donnelly S.M., et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006, 130(3):794-799.
21. Capelastegui A., Espana P.P., Quintana J.M., et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004, 39(7):955-963.
22. Yealy D.M., Auble T.E., Stone R.A., et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005, 143(12):881-894.
23. Fine M.J., Pratt H.M., Obrosky D.S., et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000, 109(5):378-385.
24. Marrie T.J., Lau C.Y., Wheeler S.L., et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000, 283(6):749-755.
25. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250.
26. Martinez R., Reyes S., Lorenzo M.J., et al. Impact of guidelines on outcome: the evidence. Semin Respir Crit Care Med 2009, 30(2):172-178.
27. Grimshaw J., Eccles M., Tetroe J. Implementing clinical guidelines: current evidence and future implications. J Contin Educ Health Prof 2004, 24(Suppl 1):S31-S37.
28. Bratzler D.W., Nsa W., Houck P.M. Performance measures for pneumonia: are they valuable, and are process measures adequate?. Curr Opin Infect Dis 2007, 20(2):182-189.
29. Werner R.M., Bradlow E.T. Relationship between Medicare's hospital compare performance measures and mortality rates. JAMA 2006, 296(22):2694-2702.
30. Measure evaluation criteria National Quality Forum, Available at:, Accessed January 24, 2011. http://www.qualityforum.org/docs/measure_evaluation_criteria.aspx.
31. Wilson K.C., Schunemann H.J. An appraisal of the evidence underlying performance measures for community-acquired pneumonia. Am J Respir Crit Care Med 2011, 183(11):1454-1462.
32. Linder J.A., Kaleba E.O., Kmetik K.S. Using electronic health records to measure physician performance for acute conditions in primary care: empirical evaluation of the community-acquired pneumonia clinical quality measure set. Med Care 2009, 47(2):208-216.
33. Wachter R.M., Flanders S.A., Fee C., et al. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008, 149(1):29-32.
34. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163(7):1730-1754.
35. Afshar N., Tabas J., Afshar K., et al. Blood cultures for community-acquired pneumonia: are they worthy of two quality measures? A systematic review. J Hosp Med 2009, 4(2):112-123.
36. Metersky M.L., Ma A., Bratzler D.W., et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004, 169(3):342-347.
37. Yu K.T., Wyer P.C. Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia. Ann Emerg Med 2008, 51(5):651-662. 662, e651-2.
38. Houck P.M. Antibiotics and pneumonia: is timing everything or just a cause of more problems?. Chest 2006, 130(1):1-3.
39. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164(6):637-644.
40. Waterer G.W., Kessler L.A., Wunderink R.G. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006, 130(1):11-15.
41. Kanwar M., Brar N., Khatib R., et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007, 131(6):1865-1869.
42. Welker J.A., Huston M., McCue J.D. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008, 168(4):351-356.
43. Polgreen P.M., Chen Y.Y., Cavanaugh J.E., et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007, 28(2):212-214.
44. Metersky M.L., Sweeney T.A., Getzow M.B., et al. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours?. Chest 2006, 130(1):16-21.
45. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170(4):440-444.
46. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161(15):1837-1842.
47. Gleason P.P., Meehan T.P., Fine J.M., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999, 159(21):2562-2572.
48. Martinez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36(4):389-395.
49. Metersky M.L., Ma A., Houck P.M., et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007, 131(2):466-473.
50. Brown R.B., Iannini P., Gross P., et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003, 123(5):1503-1511.
51. Mills G.D., Oehley M.R., Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005, 330(7489):456.
52. Shefet D., Robenshtok E., Paul M., et al. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005, 165(17):1992-2000.
53. Metersky M., Ho S.Y., Petrillo M.K. Does hospital-based influenza vaccination result in unintended revaccination?. Am J Med 2004, 116(12):854-855.
54. U.S. Department of Health and Human Services Statistical methods used to calculate rates, Available at:, Accessed January 24, 2011. http://www.hospitalcompare.hhs.gov/staticpages/for-professionals/ooc/statistcal-methods.aspx.
55. Lindenauer P.K., Normand S.L., Drye E.E., et al. Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. J Hosp Med 2011, 6(3):142-150.
56. Halm E.A., Fine M.J., Kapoor W.N., et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002, 162(11):1278-1284.
57. Ramirez J.A., Vargas S., Ritter G.W., et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999, 159(20):2449-2454.
58. Hagaman J.T., Yurkowski P., Trott A., et al. Getting physicians to make " the switch" : the role of clinical guidelines in the management of community-acquired pneumonia. Am J Med Qual 2005, 20(1):15-21.
59. Oosterheert J.J., Bonten M.J., Schneider M.M., et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006, 333(7580):1193.
60. Fishbane S., Niederman M.S., Daly C., et al. The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. Arch Intern Med 2007, 167(15):1664-1669.